Target
Tissue Factor (TF)
5 abstracts
Abstract
Phase I/II first-in-human study to evaluate the safety and efficacy of tissue factor-ADC MRG004A in patients with solid tumors.Org: Memorial Sloan Kettering Cancer Center, Fudan University Shanghai Cancer Center, University of California Irvine, the First Affiliated Hospital, Zhejiang, University School of Medicine, Shanghai Medical College, Fudan University,
Abstract
Tisotumab vedotin in 2L/3L recurrent or metastatic cervical cancer: Subsequent therapy data from ENGOT-cx12/GOG-3057/innovaTV 301.Org: Broward Health, Genmab US, Inc.,
Abstract
Tisotumab vedotin in head and neck squamous cell carcinoma: Updated analysis from innovaTV 207 Part C.Org: CEPCM AP-HM,
Abstract
Lenvatinib (LEN) combined with tislelizumab (TIS) plus transcatheter arterial chemoembolization (TACE) for unresectable hepatocellular carcinoma (uHCC): A single-arm, phase II clinical trial.Org: Guangxi Medical University Cancer Hospital, Nanning, China, China National Biotec Group, Nnanning,
Abstract
Functional roles of tissue factor and EMMPRIN/CD147 present on bladder urothelial carcinoma-derived extracellular vesicles.Org: Division of Experimental Oncology, Clinic of Hematology and Oncology, University Medical Center Schleswig-Holstein, Lübeck, Germany, Lübeck, Germany, Division of Molecular Therapy, Clinic of Hematology and Oncology, University Medical Center Schleswig-Holstein, Lübeck, Germany, Lübeck, Germany, Clinic of Urology, University Medical Center Schleswig-Holstein, Lübeck, Germany, Ratzeburger Allee 160, Lübeck, Germany, Skagit Valley Hospital Regional Cancer Care Center and The Breast Institute, Mount Vernon, WA,